Target intelligence / Profile preview

Proteasome regulatory particle subunit RPN13 (RPN13)

Target
RPN13
Molecular classification
Proteasome subunit, Ubiquitin receptor, Deubiquitinating enzyme adaptor, regulatory particle component
01

Overview

Proteasome regulatory particle subunit RPN13 (ADRM1, hRpn13) is a non-ATPase component of the 19S regulatory particle of the eukaryotic 26S proteasome. RPN13 serves as a major receptor for ubiquitinated proteins, recognizing K48-linked diubiquitin via its N-terminal Pru domain and docking these substrates for proteasomal degradation. RPN13 also recruits and activates the deubiquitinating enzyme Uch37/UCHL5, thereby coupling substrate recognition with ubiquitin chain disassembly at the proteasome. RPN13 is targeted by specific small molecule inhibitors such as RA190, which restrict tumor growth by disrupting proteasome-mediated degradation. RPN13 dysfunction or overexpression is implicated in cancer and other proteostasis-related diseases. It is essential for cellular protein quality control, immune response regulation, and general homeostasis by ensuring timely degradation of misfolded or regulatory proteins.

Other names
ADRM1hRpn13
02

Mechanism of action

RA190 targets RPN13 (covalent modification) and UCHL5, leading to inhibition of ubiquitin chain removal and induction of apoptosis in cancer cells. Disruption of ubiquitin binding and protein recognition, blocking substrate degradation.

03

Biological functions

Ubiquitin-dependent protein degradationDocking and recognition of ubiquitinated substratesBinding and activation of deubiquitinating enzyme Uch37/UCHL5Regulation of proteasome assembly and substrate processingControl of protein turnover and cellular homeostasis
04

Disease associations

Cancer (especially multiple myeloma and other solid tumors)Neurodegenerative disease (associated with dysregulated proteostasis, but evidence is indirect)Inflammation (implicated via proteasome pathway modulation)general proteostasis-related diseases
05

Safety considerations

Global inhibition of proteasome function could cause toxicity in normal cells due to the essential role in protein homeostasisOff-target effects on deubiquitination enzymes such as Uch37/UCHL5Possible immune suppression, neurotoxicity, or other adverse effects related to proteasomal inhibition
06

Interacting drugs

RA190

1 more in the full profile.

07

Biomarkers

Overexpression or mutation of RPN13 (ADRM1) in tumor cells; used as a marker for proteasome pathway activityAccumulation of ubiquitinated substrates following RPN13 disruption

Beyond the preview

Go deeper on Proteasome regulatory particle subunit RPN13 (RPN13).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Proteasome regulatory particle subunit RPN13 (RPN13).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call